Open, randomized, active-controlled insulin resistance outcome trial of safety and efficacy with empagliflozin in type 2 diabetic patients

Trial Profile

Open, randomized, active-controlled insulin resistance outcome trial of safety and efficacy with empagliflozin in type 2 diabetic patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jul 2017 Planned End Date changed from 30 Mar 2017 to 30 Mar 2018.
    • 03 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 27 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top